UGT1A1 and colorectal cancer: According to the guideline of Chinese Society of Clinical Oncology (CSCO) for colorectal cancer in 2024, it is recommended to decrease the dose of CPT-11 for patients carrying the homozygous or double heterozygous for UGT1A1*28 or UGT1A1*6.